Envestnet Portfolio Solutions Inc. Purchases 101 Shares of Penumbra, Inc. (NYSE:PEN)

Envestnet Portfolio Solutions Inc. grew its holdings in Penumbra, Inc. (NYSE:PEN) by 3.7% in the fourth quarter, HoldingsChannel reports. The fund owned 2,867 shares of the company’s stock after buying an additional 101 shares during the period. Envestnet Portfolio Solutions Inc.’s holdings in Penumbra were worth $681,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also modified their holdings of the business. True Wealth Design LLC acquired a new position in shares of Penumbra during the 3rd quarter worth approximately $26,000. UMB Bank n.a. boosted its stake in shares of Penumbra by 57.4% in the fourth quarter. UMB Bank n.a. now owns 192 shares of the company’s stock valued at $46,000 after buying an additional 70 shares during the period. Mather Group LLC. grew its position in Penumbra by 208.0% during the fourth quarter. Mather Group LLC. now owns 308 shares of the company’s stock worth $73,000 after buying an additional 208 shares in the last quarter. Jones Financial Companies Lllp lifted its position in shares of Penumbra by 25.0% during the 4th quarter. Jones Financial Companies Lllp now owns 375 shares of the company’s stock valued at $89,000 after acquiring an additional 75 shares during the period. Finally, Advisors Asset Management Inc. lifted its position in shares of Penumbra by 11.5% during the 3rd quarter. Advisors Asset Management Inc. now owns 416 shares of the company’s stock valued at $81,000 after acquiring an additional 43 shares during the period. 88.88% of the stock is currently owned by institutional investors and hedge funds.

Penumbra Stock Performance

Shares of PEN stock opened at $286.09 on Tuesday. Penumbra, Inc. has a one year low of $148.00 and a one year high of $310.00. The company has a debt-to-equity ratio of 0.02, a current ratio of 6.01 and a quick ratio of 3.25. The business’s 50 day simple moving average is $273.48 and its 200 day simple moving average is $241.14. The stock has a market capitalization of $11.02 billion, a PE ratio of 841.45, a PEG ratio of 2.83 and a beta of 0.51.

Penumbra (NYSE:PEN) last issued its quarterly earnings results on Tuesday, February 18th. The company reported $0.97 EPS for the quarter, beating analysts’ consensus estimates of $0.88 by $0.09. Penumbra had a net margin of 1.17% and a return on equity of 9.74%. The business had revenue of $315.52 million for the quarter, compared to analysts’ expectations of $311.63 million. As a group, research analysts forecast that Penumbra, Inc. will post 3.67 earnings per share for the current year.

Wall Street Analysts Forecast Growth

PEN has been the subject of several recent analyst reports. Citigroup upped their price objective on shares of Penumbra from $220.00 to $245.00 and gave the stock a “neutral” rating in a research report on Wednesday, December 11th. UBS Group boosted their price objective on shares of Penumbra from $305.00 to $320.00 and gave the company a “buy” rating in a research report on Wednesday, February 19th. JPMorgan Chase & Co. raised their target price on Penumbra from $230.00 to $285.00 and gave the company an “overweight” rating in a report on Wednesday, February 19th. BTIG Research lifted their price target on Penumbra from $232.00 to $270.00 and gave the company a “buy” rating in a research note on Tuesday, November 26th. Finally, Wells Fargo & Company upped their price objective on shares of Penumbra from $275.00 to $305.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 19th. Four equities research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $294.47.

Insider Buying and Selling

In other Penumbra news, CEO Adam Elsesser sold 16,600 shares of the stock in a transaction that occurred on Wednesday, March 19th. The stock was sold at an average price of $276.21, for a total transaction of $4,585,086.00. Following the transaction, the chief executive officer now directly owns 27,752 shares in the company, valued at approximately $7,665,379.92. This represents a 37.43 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Harpreet Grewal sold 167 shares of Penumbra stock in a transaction on Friday, January 3rd. The shares were sold at an average price of $241.28, for a total transaction of $40,293.76. Following the completion of the sale, the director now owns 8,530 shares of the company’s stock, valued at $2,058,118.40. This represents a 1.92 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 81,518 shares of company stock valued at $22,994,979 over the last 90 days. Company insiders own 5.00% of the company’s stock.

Penumbra Company Profile

Penumbra, Inc, together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX.